Abstract 5650
Background
Up to 44% of patients receiving combination ipilimumab and nivolumab develop checkpoint-inhibitor-(CI) colitis, however its molecular pathogenesis is poorly understood. We aimed to characterise peripheral blood and gut mononuclear cells (PBMC; GMNC) in patients with CI-colitis and controls to gain insights into disease aetiology. We were particularly interested in activated, memory, gut-homing CD8+ T-cells and also the innate-like mucosal-associated invariant T (MAIT) cells that play important roles in mucosal immunity.
Methods
In Cohort I PBMC from patients with CI-colitis (N = 9) were compared with those from patients who received CI with no adverse-events (CI-controls; N = 11), patients with active ulcerative colitis (UC; N = 6) and Healthy Volunteers (N = 16). PBMC findings were tested in a second cohort (Cohort II; IN-Colitis N = 15; IN-NAE=9). GMNC were isolated in Cohort III (IN-colitis N = 5; IN-controls N = 5; UC N = 6; Healthy Volunteers N = 6). Flow-cytometric analysis was used throughout.
Results
CI-colitis patients had low circulating MAIT cells compared with CI-controls at baseline in Cohort I. Low levels of circulating MAIT cells in both CI-colitis and CI-controls (compared to Healthy Volunteers) were found in Cohort II. CI-treated patients had high levels of activated-memory T-cells in peripheral blood (CD8 + >CD4+) that included a gut-homing population, regardless of the development of colitis. However, activation of circulating MAIT cells was not evident. In gut tissue there was elevation of activated, granzyme-B+ MAIT cells in CI-colitis compared with CI-controls. CI-colitis was characterised by an activated-memory CD8+ lymphocytosis.
Conclusions
Melanoma patients can have low baseline circulating MAIT cells. In one cohort this associated with CI-colitis. In tissue, activated MAIT cells were elevated in CI-colitis. Further work is needed to determine which immune populations are useful for the prediction and prognostication of CI-colitis, and if MAIT cells contribute to tissue damage or repair.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Celgene.
Disclosure
S.C. Sasson: Research grant / Funding (institution): Celgene. V.T.F. Cheung: Speaker Bureau / Expert testimony: Janssen. G.V. Long: Advisory / Consultancy: Aduro; Advisory / Consultancy: Amgen; Advisory / Consultancy: BMS; Advisory / Consultancy: Merck MSD; Advisory / Consultancy: Mass-Array; Advisory / Consultancy: Novartis; Advisory / Consultancy: Pierre Fabre; Advisory / Consultancy: Roche. M.R. Middleton: Advisory / Consultancy: Amgen; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: BMS; Advisory / Consultancy: Eisai; Advisory / Consultancy: Lilli; Advisory / Consultancy: Merck; Advisory / Consultancy: Millenium; Advisory / Consultancy: Novartis; Advisory / Consultancy: Physiomics; Advisory / Consultancy: Rignotec; Advisory / Consultancy: Roche. O. Brain: Speaker Bureau / Expert testimony: BMS; Research grant / Funding (institution): Celgene. All other authors have declared no conflicts of interest.
Resources from the same session
4868 - Evaluation of markers associated with efficacy of abiraterone acetate plus prednisone (AAP) in patients (pts) with castration-sensitive prostate cancer (mCSPC) from the LATITUDE study
Presenter: Kim Chi
Session: Poster Display session 3
Resources:
Abstract
4837 - LRP2, a potential new biomarker for Chinese younger aged intrahepatic cholangiocarcinoma patients
Presenter: Xiaoliang Shi
Session: Poster Display session 3
Resources:
Abstract
1286 - Reanalysis of the efficacy of molecular targeted agents (MTAs) given in the randomized trial SHIVA01 according to the ESMO ESCAT scale of actionability
Presenter: Aurelie Moreira
Session: Poster Display session 3
Resources:
Abstract
2736 - Comparison of Platforms for Determining Tumor Mutational Burden (TMB) From Blood Samples in Patients With Non-Small Cell Lung Cancer (NSCLC)
Presenter: Jonathan Baden
Session: Poster Display session 3
Resources:
Abstract
5045 - Comprehensive Pan-Cancer analysis of somatic mutations in drug transporters to reveal acquired and intrinsic drug resistance in 3149 metastatic cancer patients
Presenter: Sander Bins
Session: Poster Display session 3
Resources:
Abstract
4577 - Pan-Cancer Genomic Landscape of the Cyclin D1/FGF3,4,19 (11q13) Amplicon Including Associations with HPV Status, and ESR1 and AR Alterations
Presenter: Jennifer Johnson
Session: Poster Display session 3
Resources:
Abstract
5366 - Co-occurrence of NTRK fusions with other genomic biomarkers in cancer patients
Presenter: Xiaolong Jiao
Session: Poster Display session 3
Resources:
Abstract
4084 - Prospective comparative study of next-generation sequencing on fine needle aspirations versus core needle biopsies in cancer patients included in SHIVA02 trial
Presenter: Julien Masliah-Planchon
Session: Poster Display session 3
Resources:
Abstract
6017 - First national External Quality Assessement for the interpretation of somatic variants: assessment of 25 variants in colorectal, lung, ovarian cancers and melanoma in France
Presenter: Etienne Rouleau
Session: Poster Display session 3
Resources:
Abstract
2283 - Prospective testing of circulating tumor DNA in metastatic breast cancer facilitates clinical trial enrollment and precision oncology
Presenter: Andjelija Bujak
Session: Poster Display session 3
Resources:
Abstract